Lung Cancer, Nonsmall Cell Clinical Trial
Official title:
An Open-Label, Phase 1b/2a Study of SLC-391, an AXL Inhibitor, in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL with desirable potency and pharmaceutical properties. The study is being done to evaluate the safety and pharmacokinetic (PK) profile of SLC-391 in combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC). Each treatment cycle lasts 21 days. Participants will swallow SLC-391 pills two times every day. Participants will get pembrolizumab intravenously (IV) from the study site staff on the first day of every cycle. This study has 2 parts. The first part will determine the recommended dose of SLC-391 in combination with pembrolizumab. The second part wants to find out if the combination of SLC-391 and pembrolizumab can help stop NSCLC tumours from growing or spreading.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06003075 -
Induction Chemo-Nivo in Unresectable Stage III NSCLC
|
Phase 2 | |
| Enrolling by invitation |
NCT06293833 -
Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan
|
N/A | |
| Recruiting |
NCT03705806 -
Palliative Thoracic ImmunoRT
|
||
| Not yet recruiting |
NCT06060964 -
Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management
|
Early Phase 1 | |
| Completed |
NCT04634630 -
The Influence of Cancer Stem-cells on Risk of Relapse in Patients Harboring Adenocarcinoma and Squamous Cell Carcinoma of the Lung
|
||
| Completed |
NCT03689634 -
Move For Surgery - A Novel Preconditioning Program
|
Phase 3 | |
| Recruiting |
NCT05537922 -
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
|
||
| Completed |
NCT03902834 -
Move for Surgery (MFS): Evaluating the Use of Wearable Technology for Preconditioning Before Thoracic Surgery
|
N/A | |
| Active, not recruiting |
NCT03322072 -
Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating
|
N/A | |
| Completed |
NCT02995889 -
FLT-PET for Early Detection of Relapse in Patients With Irradiated Lung Cancer
|
N/A | |
| Recruiting |
NCT04237805 -
A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients
|
Phase 1/Phase 2 | |
| Terminated |
NCT05061940 -
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
|
||
| Enrolling by invitation |
NCT05863013 -
Use of the ADL-Glittre Test in the Pre and Postoperative Period of Patients With Lung Cancer
|
N/A | |
| Suspended |
NCT02991651 -
Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC
|
Phase 1 | |
| Enrolling by invitation |
NCT04678440 -
[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients
|
Early Phase 1 | |
| Recruiting |
NCT04222335 -
Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients
|
N/A | |
| Recruiting |
NCT04415320 -
X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
|
Phase 2 | |
| Recruiting |
NCT02786589 -
Plasmodium Immunotherapy for Lung Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05085028 -
A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
|
Phase 3 | |
| Recruiting |
NCT05956782 -
Breathe Easier II: A Dyad-based Multiple Behavior Intervention
|
N/A |